Stay up to date with the latest GeneReader NGS System news here:

QIAGEN launches QCI Interpret bioinformatics features for use for blood cancers as well as a novel myeloid gene panel for GeneReader NGS System

29 NOV 2018

Hilden, Germany, and Germantown, Maryland, November 29, 2018 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two novel products to deliver actionable insights on a wide range of blood cancers: a new workflow for the QIAGEN Clinical Insight (QCI) Interpret bioinformatics solution for hematological malignancies, and the new QIAact Myeloid DNA UMI Panel for use in myeloid neoplasm research as a Sample to Insight workflow on QIAGEN’s GeneReader NGS System. READ MORE...

QIAGEN expands next-generation sequencing portfolio with oncology and immuno-oncology panels for research using GeneReader NGS System and other platforms

29 OCT 2018

Hilden, Germany, and Germantown, Maryland, October 29, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of three innovative Sample to Insight workflows for next-generation sequencing (NGS) research in oncology using QIAGEN’s GeneReader NGS System and other NGS platforms. READ MORE...

QIAGEN announces broadening of GeneReader NGS System applications into hereditary disease analysis

25 JUNE 2018

Hilden, Germany, and Germantown, Maryland, June 25, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today introduced seamless next-generation sequencing (NGS) solutions for a wide range of hereditary diseases on the GeneReader NGS System, the complete Sample to Insight NGS solution for any lab worldwide. READ MORE...

QIAGEN and Natera partner to develop cutting-edge genetic testing assays for use on QIAGEN’s GeneReader NGS System

12 MARCH 2018

Hilden, Germany, and San Carlos, CA, March 12, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a world leader in providing Sample to Insight molecular solutions, and Natera, Inc. (NASDAQ: NTRA), a leading developer of next-generation sequencing (NGS) assays that include non-invasive prenatal genetic testing and the analysis of circulating tumor DNA, today announced a partnership to develop cutting-edge cell-free DNA assays for use on QIAGEN’s GeneReader NGS System. READ MORE...

QIAGEN adds to growth momentum in next-generation sequencing with 2018 plans for significant portfolio enhancements

8 JANUARY 2018

Hilden, Germany, and Germantown, Maryland, January 8, 2018 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a range of product and service enhancements to its next-generation sequencing (NGS) portfolio, which offers universal solutions for use with any NGS sequencer as well as the GeneReader NGS System*, the world's first complete Sample to Insight solution based on proprietary chemistry that makes the benefits of NGS accessible to any laboratory. QIAGEN has set a goal to exceed $140 million in 2018 sales from this portfolio, up from over $115 million in 2017. READ MORE...

QIAGEN’s GeneReader NGS System delivers accuracy and ease of use for clinical research in oncology

14 NOVEMEBER 2017

Hilden, Germany, and Germantown, Maryland, November 14, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced new studies highlighting the outstanding analytical performance and ease of use of the GeneReader NGS System, the world's first complete Sample to Insight solution for next-generation sequencing. The studies are being presented this week at the Association for Molecular Pathology (AMP) 2017 Annual Meeting in Salt Lake City, Utah, where QIAGEN also will demonstrate the GeneReader and other Sample to Insight solutions. READ MORE...

QIAGEN and ICMP launch next-generation DNA testing solutions for identifying missing persons

24 OCTOBER 2017

The Hague, 24 October 2017 – The International Commission on Missing Persons (ICMP) today announced the launch of a cutting-edge next-generation sequencing (NGS) workflow created in collaboration with QIAGEN N.V. for ICMP's missing persons DNA identification laboratory in The Hague. The solution integrates QIAGEN’s GeneReader NGS System and spans all aspects of the DNA laboratory workflow, from sample extraction through final analysis and thereby creates a unique “sample to insight” user experience. The workflow includes automated QIAGEN instruments and consumables for DNA extraction, liquid handling, quantification, sample preparation and next generation, Massively Parallel Sequencing (MPS). READ MORE...

Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

3 JUNE 2017

NEW YORK and HILDEN, Germany, (June 3, 2017) – Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer treatment. This will leverage the combination of Bristol-Myers Squibb’s portfolio of I-O therapies with QIAGEN’s proven track record in developing and commercializing companion and complementary diagnostics as well as QIAGEN’s portfolio of NGS technologies. I-O therapies offer a novel way to treat cancer by using drugs to target the body’s immune system to help fight cancer. READ MORE...

QIAGEN partners with Maccura to localize and commercialize GeneReader NGS System in China

2 MAY 2017

Hilden, Germany, and Chengdu, China, May 2, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a joint venture with Maccura Biotechnology Co., Ltd., a leading in vitro diagnostics (IVD) company in China. The joint venture, named MAQGEN plans to accelerate local adaptations, development and commercialization of the GeneReader NGS System in the rapidly growing clinical and clinical research markets in China. QIAGEN’s GeneReader NGS System is the world’s first complete Sample to Insight solution and makes the benefits of next-generation sequencing (NGS) accessible to any laboratory. READ MORE...

QIAGEN’s GeneReader NGS System gains further validation in oncology research applications with new independent performance review data

3 APRIL 2017

Hilden, Germany, April 3, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced further validation of the GeneReader NGS System with the publication of five new independent studies that reaffirm the analytical performance and ease in using the world’s first complete Sample to Insight solution that makes the benefits of next-generation sequencing (NGS) accessible to any laboratory. READ MORE...

QIAGEN announces comprehensive range of enhancements for GeneReader NGS System

9 JANUARY 2017

Germantown, Maryland, and Hilden, Germany, January 9, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a comprehensive range of enhancements for the GeneReader NGS System* – in particular the launch of new gene panels that will create a full menu for oncology applications – that are designed to significantly improve the utility, efficiency and cost-effectiveness of the world’s first Sample to Insight next-generation sequencing (NGS) solution. READ MORE...

The GeneReader NGS System is for Research Use Only. Not for use in diagnostic procedures.